Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
18
Dec |
FDA Approves Hologic’s Cervista High Throughput Automation System For Cervical Cancer ScreeningCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the U.S…
|
21
Apr |
FDA Approves Roche’s HPV Test For Identifying Women At Highest Risk For Cervical CancerCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may prevent many women from developing this deadly disease…
|
22
Mar |
New Test Reduces False Positive Results For HPVCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
A new test for human papillomavirus (HPV) is just as sensitive as the old one, but more specific for detecting cervical cancer, meaning that it has fewer false positive results, according to a paper in the February 2011 Journal of Clinical Microbiology…
|
25
Feb |
Pivotal Study Validates Roche’s Cobas® HPV Test With HPV-16 And 18 Genotyping For Identifying Women At Highest Risk For Cervical CancerCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a study published online in the American Journal of Clinical Pathology demonstrated the ability of the cobas HPV Test to individually detect HPV-16 and HPV-18, two of the highest risk HPV genotypes causing 70 percent of cervical cancer cases…
|
25
Feb |
Pivotal Study Validates Roche’s Cobas® HPV Test With HPV-16 And 18 Genotyping For Identifying Women At Highest Risk For Cervical CancerCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a study published online in the American Journal of Clinical Pathology demonstrated the ability of the cobas HPV Test to individually detect HPV-16 and HPV-18, two of the highest risk HPV genotypes causing 70 percent of cervical cancer cases…
|
24
Nov |
New Cervical Cancer Screening Test Set To Save The Lives Of Women All Over The UKCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
The largest ever registrational study for a diagnostic product, involving more than 47,000 women shows that the cobas(R) 4800 Human Papillomavirus (HPV) test from Roche, is able to improve the detection of pre-cancerous cells in women whose cervical smears tested normal…
|
12
Oct |
Roche And German Cancer Research Center (DKFZ) Enter Research Agreement To Predict Cervical CancerCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) and the German Cancer Research Center (DKFZ) announced that they have entered into a research collaboration to enable more specific prediction of a woman’s risk for developing cervical cancer. The collaboration is based on recent DKFZ research indicating that the relative amounts of specific spliced viral RNA molecules (i.e…
|
29
Sep |
Guided Therapeutics Files Premarket Approval Application For Non-Invasive Cervical Cancer Scanner With FDACategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Guided Therapeutics, Inc. (OTCBB: GTHP) announced that it filed its completed premarket approval application (PMA) for the LightTouch™ Cervical Scanner with the U.S. Food and Drug Administration (FDA) for patients at risk for cervical cancer…
Guided Therapeutics, Inc. (GT) (OTCBB: GTHP) announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009. The three-year grant provides additional resources to commercialize and bring to market the LightTouch™ non-invasive cervical cancer detection device and single-patient-use disposable…
|
13
Jul |
Study From First Latin American Country To Implement National HPV Testing Program Shows Successful Cervical Cancer ControlCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
A study released “online first” in Cancer Causes & Control demonstrates that human papillomavirus (HPV) testing, using QIAGEN’s digene® HPV Test, improved cervical cancer control compared to routine Pap (cytology) testing among 50,000 women across Mexico, the first country in Latin America to implement a national screening program for the high-risk (HR) types of HPV that ca…